BioVie Inc. announced on May 15, 2025, the enrollment of the first patient in its Phase 2 ADDRESS-LC clinical trial. This trial is evaluating bezisterim, a novel anti-inflammatory candidate, for the treatment of neurological symptoms associated with Long COVID, including debilitating fatigue and brain fog.
The company emphasized that despite the growing recognition of Long COVID as a serious condition, diagnosed patients currently lack approved treatment options. Evidence suggests that sustained inflammation plays a central role in the pathogenesis of Long COVID, particularly in cognitive dysfunction.
Bezisterim targets key underlying mechanisms of neuroinflammation, and previous studies have indicated its potential to reduce chronic symptoms in Alzheimer's disease and Parkinson's disease. This trial represents a crucial step in addressing a significant unmet medical need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.